Group items tagged

Krishna Eye and Ent hospital is specialised in Neuro Ophthalmology. Eye hospital specialising in neurosurgery, cosmetic ophthalmology, schwannoma surgery, diplopia treatment and optic nerve treatment.

The General Pharmaceutical Council (GPhC) has appointed a new provider, BTL Group Ltd, to conduct its common registration assessment sittings, which it holds jointly with the Pharmaceutical Society of Northern Ireland (PSNI). GPhC chief executive, Duncan Rudkin, said: "I'm pleased to confirm that we have appointed BTL as the supplier for the common registration assessment for the next 3 years after a thorough tender process. "The information provided by BTL during the tender process has given us the necessary assurance that they can support us in continuing to deliver a fair and robust assessment that tests candidates' ability to register as a pharmacist. We will now work closely with BTL on arrangements for the sittings in 2022, to make sure we can provide a positive experience for candidates." BTL has extensive experience of delivering services to a range of clients, including the Royal College of Paediatrics and Child Health and the Royal College of Ophthalmology. Before BTL, GPhC had a contract with Pearson Vue to conduct online assessment in 2021.

Drugmaker Viatris said on Sunday (October 1) it had reached agreements to divest some of its businesses for a total of about £2.9 billion. Viatris said its move to divest some of its businesses is part of its long-term strategy to streamline focus on three core therapeutic areas - ophthalmology, gastroenterology and dermatology. The company has received an offer of about $2.17 billion (£1.78 billion) for almost all of its over-the-counter drug business from France-based Cooper Consumer Health. Viatris will retain rights for erectile dysfunction drug Viagra, nasal spray Dymista and select OTC drugs within certain markets. Separately, the drugmaker said it has agreed to sell its women's healthcare business to Spanish pharmaceutical company Insud Pharma, while its active pharmaceutical ingredients business in India will be sold to Iquest Enterprises. Both divestitures would result in about $1.2 billion (£987 million) in proceeds.